A tandem CD19/CD20 CAR lentiviral vector drives on-target and off-target antigen modulation in leukemia cell lines

Journal for ImmunoTherapy of Cancer

Volumn 5, Issue 1, 2017, Pages

  Schneider, Dina ^a   Xiong, Ying ^a   Wu, Darong ^a   Nölle, Volker ^b   Schmitz, Sarah ^b   Haso, Waleed ^a   Kaiser, Andrew ^b   Dropulic, Boro ^a   Orentas, Rimas J ^a  

^a Lentigen Corporation   (United States)

^b MILTENYI BIOTEC GMBH   (Germany)

Author keywords

Adoptive immunotherapy; CAR T; CD19; CD20; CD22; Hematologic malignancy; Lentiviral vector; Tandem targeting CAR; Tumor antigen escape

Indexed keywords

CD19 ANTIGEN; CD20 ANTIGEN; CD22 ANTIGEN; CHIMERIC ANTIGEN RECEPTOR; CYTOKINE; LENTIVIRUS VECTOR; CD19 MOLECULE, HUMAN; TUMOR ANTIGEN;

ANIMAL CELL; ARTICLE; CELL KILLING; CELL MEDIATED CYTOTOXICITY; CHROMATOGRAPHY; CONTROLLED STUDY; FLOW CYTOMETRY; HEMATOLOGIC MALIGNANCY; HUMAN; HUMAN CELL; IMMUNOASSAY; LEUKEMIA CELL LINE; MOUSE; MUTATION; NALM 6 CELL LINE; NONHUMAN; PRIORITY JOURNAL; WESTERN BLOTTING; ADOPTIVE IMMUNOTHERAPY; ANIMAL; BIOSYNTHESIS; BURKITT LYMPHOMA; CYTOTOXICITY; DRUG SCREENING; GENE VECTOR; GENETICS; IMMUNOLOGY; INBRED MOUSE STRAIN; LENTIVIRUS; LEUKEMIA; PROCEDURES; T LYMPHOCYTE; TRANSPLANTATION; TUMOR CELL LINE; TUMOR ESCAPE;

ANIMALS; ANTIGENS, CD19; ANTIGENS, CD20; ANTIGENS, NEOPLASM; BURKITT LYMPHOMA; CELL LINE, TUMOR; CYTOKINES; CYTOTOXICITY, IMMUNOLOGIC; GENETIC VECTORS; HUMANS; IMMUNOTHERAPY, ADOPTIVE; LENTIVIRUS; LEUKEMIA; MICE, INBRED STRAINS; T-LYMPHOCYTES; TUMOR ESCAPE; XENOGRAFT MODEL ANTITUMOR ASSAYS;

EID: 85019183285     PISSN: None     EISSN: 20511426     Source Type: Journal    
DOI: 10.1186/s40425-017-0246-1     Document Type: Article

References (30)

1. Lee DW, et al. The future is now: chimeric antigen receptors as new targeted therapies for childhood cancer. Clin Cancer Res. 2012;18(10):2780-90.
2. Kochenderfer JN, et al. Construction and pre-clinical evaluation of an anti-CD19 chimeric antigen receptor. J Immunother. 2009;32(7):689.
3. Jensen M, et al. CD20 is a molecular target for scFvFc: zeta receptor redirected T cells: implications for cellular immunotherapy of CD20+ malignancy. Biol Blood Marrow Transplant. 1998;4(2):75-83.
4. Lee DW, et al. T cells expressing CD19 chimeric antigen receptors for acute lymphoblastic leukaemia in children and young adults: a phase 1 dose-escalation trial. Lancet. 2015;385(9967):517-28.
5. Grupp SA, et al. Chimeric antigen receptor-modified T cells for acute lymphoid leukemia. N Engl J Med. 2013;368(16):1509-18.
6. Porter DL, et al. Chimeric antigen receptor-modified T cells in chronic lymphoid leukemia. N Engl J Med. 2011;365(8):725-33.
7. Kochenderfer JN, et al. B-cell depletion and remissions of malignancy along with cytokine-associated toxicity in a clinical trial of anti-CD19 chimeric-antigen-receptor-transduced T cells. Blood. 2012;119(12):2709-20.
8. Sotillo E, et al. Convergence of acquired mutations and alternative splicing of CD19 enables resistance to CART-19 immunotherapy. Cancer Discov. 2015;5(12):1282-95.
9. Ginaldi L, et al. Levels of expression of CD19 and CD20 in chronic B cell leukaemias. J Clin Pathol. 1998;51(5):364-9.
10. Barrett DM, et al. Noninvasive bioluminescent imaging of primary patient acute lymphoblastic leukemia: a strategy for preclinical modeling. Blood. 2011;118(15):e112-7.
11. Wu AM, et al. Multimerization of a chimeric anti-CD20 single-chain Fv-Fc fusion protein is mediated through variable domain exchange. Protein Eng. 2001;14(12):1025-33.
12. Whitlow M, et al. An improved linker for single-chain Fv with reduced aggregation and enhanced proteolytic stability. Protein Eng. 1993;6(8):989-95.
13. Haso W, et al. Anti-CD22-chimeric antigen receptors targeting B-cell precursor acute lymphoblastic leukemia. Blood. 2013;121(7):1165-74.
14. Kuroda H, et al. Simplified lentivirus vector production in protein-free media using polyethylenimine-mediated transfection. J Virol Methods. 2009;157(2):113-21.
15. Vilpo J, et al. Surface membrane antigen expression changes induced in vitro by exogenous growth factors in chronic lymphocytic leukemia cells. Leukemia. 2002;16:1691-8.
16. Grada Z, et al. TanCAR: a novel bispecific chimeric antigen receptor for cancer immunotherapy. Mol Ther Nucleic Acids. 2013;2(7):e105.
17. Zah E, et al. T cells expressing CD19/CD20 bi-specific chimeric antigen receptors prevent antigen escape by malignant B cells. Cancer Immunol Res. 2016;4(6):498-508.
18. Hudecek M, et al. Receptor affinity and extracellular domain modifications affect tumor recognition by ROR1-specific chimeric antigen receptor T cells. Clin Cancer Res. 2013;19(12):3153-64.
19. Grupp SA, et al. Durable remissions in children with relapsed/refractory aLL treated with T cells engineered with a CD19-targeted chimeric antigen receptor (CTL019). Blood. 2015;126(23):681.
20. Ruella M, et al. Dual CD19 and CD123 targeting prevents antigen-loss relapses after CD19-directed immunotherapies. J Clin Invest. 2016;126(10):3814.
21. Onea AS, Jazirehi AR. CD19 chimeric antigen receptor (CD19 CAR)-redirected adoptive T-cell immunotherapy for the treatment of relapsed or refractory B-cell Non-Hodgkin's Lymphomas. Am J Cancer Res. 2016;6(2):403.
22. Anurathapan U, Chan RC, Hindi HF, Mucharla R, Bajgain P, Hayes BC, Fisher WE, Heslop HE, Rooney CM, Brenner MK, Leen AM, Vera JF. Kinetics of tumor destruction by chimeric antigen receptor-modified T cells. Mol Ther. 2014;22(3):623-33.
23. Jacoby E, et al. CD19 CAR immune pressure induces B-precursor acute lymphoblastic leukaemia lineage switch exposing inherent leukaemic plasticity. Nat Commun. 2016;7:12320.
24. Gardner R, et al. Acquisition of a CD19-negative myeloid phenotype allows immune escape of MLL-rearranged B-ALL from CD19 CAR-T-cell therapy. Blood. 2016;127(20):2406-10.
25. Otero DC, Rickert RC. CD19 function in early and late B cell development. II. CD19 facilitates the pro-B/pre-B transition. J Immunol. 2003;171(11):5921-30.
26. Otero DC, Anzelon AN, Rickert RC. CD19 function in early and late B cell development: I. Maintenance of follicular and marginal zone B cells requires CD19-dependent survival signals. J Immunol. 2003;170(1):73-83.
27. Beers SA, et al. Antigenic modulation limits the efficacy of anti-CD20 antibodies: implications for antibody selection. Blood. 2010;115(25):5191-201.
28. Depoil D, et al. CD19 is essential for B cell activation by promoting B cell receptor-antigen microcluster formation in response to membrane-bound ligand. Nat Immunol. 2008;9(1):63-72.
29. Chung EY, et al. CD19 is a major B cell receptor-independent activator of MYC-driven B-lymphomagenesis. J Clin Invest. 2012;122(6):2257-66.
30. Poe JC, et al. A c-Myc and surface CD19 signaling amplification loop promotes B cell lymphoma development and progression in mice. J Immunol. 2012;189(5):2318-25.